Skip to Content
Søg Menu

Cladribine Shows a Robust Safety Profile – Both as First-Line and Subsequent Therapy in MS

/ Jan Andreasen
ECTRIMS25MS
Linda Forsberg

ECTRIMS 2025: Swedish Real-World MS Data Demonstrates Long-Term Safety and Effectiveness of Cladribine

/ Linda Forsberg
ECTRIMS25MS Play the Video
Nicolò Tedone

EAN 2025: Need for Tailored Assessment and Monitoring of Late-Onset MS

/ Nicolò Tedone
EAN25MS Play the Video
Mark S. Freedman

Treatment That Can Be Given in a Short Period of Time and Produce a Durable Response Would Lead to Better Safety for the Patients with MS

/ Mark S. Freedman
MS Play the Video
Patricia K. Coyle

MS Is Becoming a Milder Disease in the Near Future, Enabling a Normal Life

/ Patricia K. Coyle
MS Play the Video
Gavin Giovannoni

Paradigm Shift in the Treatment of Multiple Sclerosis

/ Gavin Giovannoni
MS Play the Video
Gavin Giovannoni

Cladribine in MS: A Key to Slowing Aging and Protecting Brain Health

/ Gavin Giovannoni
MS Play the Video
Hans Lassmann

The Role of Neuropathology in Advancing Understanding of Multiple Sclerosis

/ Hans Lassmann
MS Play the Video
Marcello Moccia

A Step Forward Toward a Global Understanding of MS

/ Marcello Moccia
Neurologipäivät24MS Play the Video
Per Soelberg Sørensen

What Is New within the Optimization of Multiple Sclerosis Care?

/ Per Soelberg Sørensen
MS Play the Video
Sahla El Mahdaoui

The effects of anti-CD20 therapy on TFH cells in relapsing-remitting MS

/ Sahla El Mahdaoui
ECTRIMS24MS Play the Video
Lene Von Kappelgaard

DMTs During Pregnancy in Women with MS Do Not Affect Relapse Rates in Postpartum Periods

/ Lene Von Kappelgaard
ECTRIMS24MS Play the Video
Hent flere
Back to top